Fahd Adeeb

Fahd Adeeb

Auto-generated profile, based on publicly available information

Fahd Adeeb

RCSI & UCD Malaysia Campus, George Town, Malaysia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Joint Bone Spine
Verified
Journal Article
Closed access
MHMuhammad Haroon
Muhammad Haroon
FAFahd Adeeb
Fahd Adeeb
AEAhmed Eltahir
Ahmed Eltahir
SHSinead Harney
Sinead Harney

4 April 2011 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MHMuhammad Haroon
Muhammad Haroon
FAFahd Adeeb
Fahd Adeeb
JDJoe Devlin
Joe Devlin
DODonncha O`gradaigh
Donncha O`gradaigh
FWFrank Walker
Frank Walker

30 July 2013 in JRSM Short Reports
Verified
Journal Article
Open access
MHMuhammad Haroon
Muhammad Haroon
FYFaiza Yasin
Faiza Yasin
SGSyed Khurram Mushtaq Gardezi
Syed Khurram Mushtaq Gardezi
FAFahd Adeeb
Fahd Adeeb
FWFrank Walker
Frank Walker
Objectives: To evaluate the appropriateness of proton pump inhibitor (PPI) prescribing by conducting an audit of medical inpatients against recommended guidelines. Design: Questionnaire-based study. All medical wards were audited and different information was documented by patients' medical records review (both hospital visit notes and general practitioner's letters) and short interview, where we asked them to name the clinical reason for using PPI. Setting: This study was carried out in the setting of a regional hospital (537-bed, secondary care referral centre) in Ireland. Participants: The study participants were all consecutive medical patients admitted to the medical wards at Waterford Regional Hospital, Waterford. Main outcome measures: The appropriateness of PPI usage in our regional hospital by assessing the level of its prescribing against published guidelines (NICE, 2000). Results: During the audit period, 205 consecutive medical inpatients were assessed. Seventy-nine percent (162 out of 205) of the studied patients were found to be using PPI. For 45% ( n = 73) of patients, there was no documentation of valid indication for being on PPI. Overall, 64% of patients were prescribed PPI by hospital doctors, either during their current or previous admissions. We noted that 31% ( n = 51) of patients were taking PPI for ≥2 years and another 25% of patients were using PPI for about one year. Only 12% ( n = 20) of patients had undergone endoscopy procedures. Conclusion: Inappropriate use of PPI remains common in hospital practice. The risks of using long-term PPI must be weighed against the benefits.

1 June 2017 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
FAFahd Adeeb
Fahd Adeeb
SAShakeel Anjum
Shakeel Anjum
PHPhilip Hodnett
Philip Hodnett
AKAhmad Kashif
Ahmad Kashif
MBMary Brady
Mary Brady
AFAlexander Duncan Fraser
Alexander Duncan Fraser

10 September 2017 in International Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
FAFahd Adeeb
Fahd Adeeb
ASAustin G. Stack
Austin G. Stack
AFAlexander D. Fraser
Alexander D. Fraser
Behçet’s disease (BD) is a chronic relapsing vasculitis that affects vessels of all types and sizes with a broad spectrum of phenotypic heterogeneity and complex immunopathogenesis. Efforts by the scientific community to resolve the unmet needs of BD and gaps in our knowledge have been hampered by considerable challenges that primarily relate to the rare nature of the disease in many parts of the world and its heterogeneity. Controversies remain in many aspects of the disease including the diagnostic criteria, immunopathogenesis and biomarker discovery, geographical variation, and therapeutic considerations. In this review, we highlight recent advances in our scientific understanding of BD, shed new insights into diagnostic and treatment strategies, and discuss residual gaps in our knowledge that will serve as the basis for current and future research.

18 June 2013 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
FAFahd Adeeb Mohamed Ashraf
Fahd Adeeb Mohamed Ashraf
SAShakeel Anjum
Shakeel Anjum
AHAbid Hussaini
Abid Hussaini
AFAlexander Fraser
Alexander Fraser
Aortitis is uncommon but well described in patients with polymyalgia rheumatica (PMR). While glucocorticoid remains the mainstay therapy for large-vessel vasculitis, there have been cases where tocilizumab therapy led to clinical and serological improvement in patients with relapsing or refractory disease. We report a case of life-threatening PMR with aortitis in the absence of manifestations related to giant cell arteritis, which, having failed to respond to corticosteroid therapy, was successfully treated with tocilizumab and emergency reconstruction of the ascending aorta. This case adds to the literature supporting the potential value of interleukin-6 inhibition in rare rheumatological conditions such as inflammatory aortitis.